Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8757622 | Contemporary Clinical Trials | 2018 | 9 Pages |
Abstract
We propose a two-stage strategy, called the Limb-Leaf method, to explore the dose-response curve using dose promotion and addition in the context of adaptive seamless Phase II/III trials. Strong control of the overall type 1 familywise error rate of the proposed method is enforced by the closed testing principle. The design constants are determined to minimize the risk-adjusted expected total sample size while maintaining a target power. In the case of a nonmonotonic dose response curve where more doses are required to adequately explore the curve, substantial savings in sample size are achieved compared with a traditional strategy which offers only selection and promotion from among initial first stage doses.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
John Spivack, Bin Cheng, Bruce Levin,